Cargando…

Comparison of treatment strategies for patients with limited-stage small cell lung cancer who received chemotherapy

BACKGROUND: The standard care for limited-stage small cell lung cancer (SCLC) is unclear. The purpose of this study is to compare the outcome for patients receiving chemotherapy alone, chemotherapy plus surgery (CS), chemotherapy plus radiation (CR), or chemotherapy plus surgery and radiation (CSR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Shenhai, Wei, Bo, Tian, Jintao, Song, Xiaoping, Wu, Bingqun, Hu, Pengcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797666/
https://www.ncbi.nlm.nih.gov/pubmed/35117427
http://dx.doi.org/10.21037/tcr.2019.12.13
_version_ 1784641606649905152
author Wei, Shenhai
Wei, Bo
Tian, Jintao
Song, Xiaoping
Wu, Bingqun
Hu, Pengcheng
author_facet Wei, Shenhai
Wei, Bo
Tian, Jintao
Song, Xiaoping
Wu, Bingqun
Hu, Pengcheng
author_sort Wei, Shenhai
collection PubMed
description BACKGROUND: The standard care for limited-stage small cell lung cancer (SCLC) is unclear. The purpose of this study is to compare the outcome for patients receiving chemotherapy alone, chemotherapy plus surgery (CS), chemotherapy plus radiation (CR), or chemotherapy plus surgery and radiation (CSR) for limited-stage SCLC. METHODS: Patients with T1-4N0-2M0 SCLC who received chemotherapy from 2004 to 2014 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. The overall survival (OS) of these patients, stratified by different stage, was compared in accordance to the method of receiving different treatments using Kaplan-Meier method and Cox regression analysis. RESULTS: A total of 7,204 patients were included, where 1,347 (18.7%) patients received chemotherapy alone, 296 (4.1%) undergone CS, 5,296 (73.5%) patients were subjected to CR and 267 (3.7%) patients were managed by the three combination of CSR. Chemotherapy alone was associated with the worst survival in comparison to the other two method of combination i.e., chemotherapy with radiation or surgery. When compared with CR, CS had no survival benefit in patients with stage in excess of T1-2N0 disease, but was associated with improved 5-year OS in patients with T1-2N0 disease, which ranged from 29.1% to 54.3% (P<0.001). For patients with T1-2N2 disease who received CSR demonstrated superior OS over those who received CR (P=0.004) or CS (P=0.036). Cox regression analysis showed CS was associated with improved OS when compared with CR in patients with N0 disease (HR, 0.54; 95% CI, 0.43–0.68; P=0.000) and CSR was associated with better OS in comparison with CR in patients with N2 disease (HR, 0.71; 95% CI, 0.55–0.93; P=0.013). CONCLUSIONS: Patients with limited-stage SCLC can benefit from local treatment such as surgery, radiation, and surgery plus radiation. For patients with N0 disease, CS was associated with improved survival in comparison to CR. If N2 was identified after surgery, radiation may be added to improve OS.
format Online
Article
Text
id pubmed-8797666
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87976662022-02-02 Comparison of treatment strategies for patients with limited-stage small cell lung cancer who received chemotherapy Wei, Shenhai Wei, Bo Tian, Jintao Song, Xiaoping Wu, Bingqun Hu, Pengcheng Transl Cancer Res Original Article BACKGROUND: The standard care for limited-stage small cell lung cancer (SCLC) is unclear. The purpose of this study is to compare the outcome for patients receiving chemotherapy alone, chemotherapy plus surgery (CS), chemotherapy plus radiation (CR), or chemotherapy plus surgery and radiation (CSR) for limited-stage SCLC. METHODS: Patients with T1-4N0-2M0 SCLC who received chemotherapy from 2004 to 2014 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. The overall survival (OS) of these patients, stratified by different stage, was compared in accordance to the method of receiving different treatments using Kaplan-Meier method and Cox regression analysis. RESULTS: A total of 7,204 patients were included, where 1,347 (18.7%) patients received chemotherapy alone, 296 (4.1%) undergone CS, 5,296 (73.5%) patients were subjected to CR and 267 (3.7%) patients were managed by the three combination of CSR. Chemotherapy alone was associated with the worst survival in comparison to the other two method of combination i.e., chemotherapy with radiation or surgery. When compared with CR, CS had no survival benefit in patients with stage in excess of T1-2N0 disease, but was associated with improved 5-year OS in patients with T1-2N0 disease, which ranged from 29.1% to 54.3% (P<0.001). For patients with T1-2N2 disease who received CSR demonstrated superior OS over those who received CR (P=0.004) or CS (P=0.036). Cox regression analysis showed CS was associated with improved OS when compared with CR in patients with N0 disease (HR, 0.54; 95% CI, 0.43–0.68; P=0.000) and CSR was associated with better OS in comparison with CR in patients with N2 disease (HR, 0.71; 95% CI, 0.55–0.93; P=0.013). CONCLUSIONS: Patients with limited-stage SCLC can benefit from local treatment such as surgery, radiation, and surgery plus radiation. For patients with N0 disease, CS was associated with improved survival in comparison to CR. If N2 was identified after surgery, radiation may be added to improve OS. AME Publishing Company 2020-02 /pmc/articles/PMC8797666/ /pubmed/35117427 http://dx.doi.org/10.21037/tcr.2019.12.13 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Original Article
Wei, Shenhai
Wei, Bo
Tian, Jintao
Song, Xiaoping
Wu, Bingqun
Hu, Pengcheng
Comparison of treatment strategies for patients with limited-stage small cell lung cancer who received chemotherapy
title Comparison of treatment strategies for patients with limited-stage small cell lung cancer who received chemotherapy
title_full Comparison of treatment strategies for patients with limited-stage small cell lung cancer who received chemotherapy
title_fullStr Comparison of treatment strategies for patients with limited-stage small cell lung cancer who received chemotherapy
title_full_unstemmed Comparison of treatment strategies for patients with limited-stage small cell lung cancer who received chemotherapy
title_short Comparison of treatment strategies for patients with limited-stage small cell lung cancer who received chemotherapy
title_sort comparison of treatment strategies for patients with limited-stage small cell lung cancer who received chemotherapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797666/
https://www.ncbi.nlm.nih.gov/pubmed/35117427
http://dx.doi.org/10.21037/tcr.2019.12.13
work_keys_str_mv AT weishenhai comparisonoftreatmentstrategiesforpatientswithlimitedstagesmallcelllungcancerwhoreceivedchemotherapy
AT weibo comparisonoftreatmentstrategiesforpatientswithlimitedstagesmallcelllungcancerwhoreceivedchemotherapy
AT tianjintao comparisonoftreatmentstrategiesforpatientswithlimitedstagesmallcelllungcancerwhoreceivedchemotherapy
AT songxiaoping comparisonoftreatmentstrategiesforpatientswithlimitedstagesmallcelllungcancerwhoreceivedchemotherapy
AT wubingqun comparisonoftreatmentstrategiesforpatientswithlimitedstagesmallcelllungcancerwhoreceivedchemotherapy
AT hupengcheng comparisonoftreatmentstrategiesforpatientswithlimitedstagesmallcelllungcancerwhoreceivedchemotherapy